in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Merck to acquire biopharmaceutical company Idenix for $3.85 billion
1:06 PM MDT | June 11, 2014 | Natasha Alperowicz
Merck said today that it has entered into a definitive agreement to acquire of biopharmaceuticals company Idenix Pharmaceuticals (Cambridge, MA) for $24.50/share in cash. The boards of directors of both companies have approved the transaction, which values the deal at approximately $3.85 billion. “Idenix has established a promising portfolio of hepatitis C candidates based on its expertise in nucleoside/nucleotide chemistry and prodrug technologies. Idenix’s investigational hepatitis C candidates complement our promising therapies in development and...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee